YUTREPIA® (treprostinil) inhalation powder net product sales of $222.7 million in the third quarter of 2026, up 31% from the second quarter of 2026 October 2026 total patient shipments reached their highest monthly level since launch Resolved all litigation with United Therapeutics through a global